Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.

Publication/Presentation Date

10-1-2016

Abstract

Anticoagulation is essential in patients with ST elevation myocardial infarction (STEMI) to prevent further thrombosis and to maintain patency of the infarct-related artery after reperfusion. The various anticoagulant medications available for use in patients with STEMI include unfractionated heparin (UFH), low-molecular-weight heparin, fondaparinux, and bivalirudin, a direct thrombin inhibitor. The authors review the current anticoagulation strategies for patients with STEMI undergoing primary percutaneous coronary intervention (PCI), fibrinolysis, or no reperfusion. The authors present the latest evidence and controversies on this topic, with a focus on bivalirudin versus UFH in the setting of primary PCI for STEMI.

Volume

5

Issue

4

First Page

497

Last Page

511

ISSN

2211-7466

Disciplines

Medicine and Health Sciences

PubMedID

28581998

Department(s)

Department of Medicine, Cardiology Division

Document Type

Article

Link to Full Text

Share

COinS